FDA approves Nabriva’s Xenleta

Nabriva has received its first FDA approval for Xenleta, a drug used to treat community-acquired bacterial-pneumonia (CABP) in adults. CABP affects around 5 million Americans each year. The drug, which can be given orally or intravenously, is the first in a new class of antibiotics called pleuromutilins, which target a different protein synthesis binding site than older competitors.

Click here to view the entire article.